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Background Exposure to environmental tobacco smoke (ETS) has been shown to increase the risk for cardiovascular
diseases and death, and autonomic dysfunction (specifically, reduced heart rate variability (HRV)) is a
predictor of increased cardiac risk. This study tests the hypothesis that ETS exposure reduces HRV in the
general population and discusses possible pathways.
Methods This cross-sectional study was conducted between 2001 and 2003 and is part of the SAPALDIA (Swiss Cohort
Study on Air Pollution and Lung Diseases in Adults) study.
The analysis included 1218 randomly selected non-smokers aged 50 and above who participated in 24-h
electrocardiogram recordings. Other examinations included an interview, investigating health status
(especially respiratory and cardiovascular health and health relevant behaviours and exposure to ETS) and
measurements of blood pressure, body height and weight.
Results Subjects exposed to ETS at home or at work for more than 2 h/day had a difference of 15% in total power
(95%CI: 26 to 3%), low frequency power (28 to 1%), low/high frequency ratio (26 to 3%) and
18% (29 to 4%) in ultralow frequency power of HRV compared with subjects not exposed to ETS at
home or work. We also found a 2.7% (0.01 to 5.34%) higher heart rate during the recording in exposed
subjects.
Conclusions Exposure to ETS at home and work is associated with lower HRV and with higher heart rate in an ageing
population. Our findings suggest that exposure to ETS increases cardiac risk through disturbances in the
autonomic nervous system.
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Background
Exposure to environmental tobacco smoke (ETS) and reduced
heart rate variability (HRV) in middle-aged and elderly subjects,1
survivors of myocardial infarction,2 or patients with other
cardiovascular diseases3,4 are both known to be associated with
increased cardiovascular morbidity and mortality.5–10 HRV,
a widely used measure of cardiac autonomic control,11 reflects
autonomic modulation of the rhythmic activity of the sinus
node.11 To date, little has been reported on the association
between ETS exposure and HRV, heart rate, or blood pressure,
the alterations of which may be steps in the pathophysiological
pathway leading from ETS exposure to cardiopulmonary disease.
To our knowledge, the effect of longer-term exposures to ETS on
HRV has not been analysed. Short-term effects have been
described by Pope, who found a reduction in HRV in 16 never
smoking subjects equipped with Holter monitors, who were
moved from the non-smoking section of an airport to the
smoking lounge.12 Reports from the 1991 SAPALDIA (Swiss
Cohort Study on Air Pollution and Lung Diseases in Adults)
study13 describe the effects of ETS on respiratory symptoms in
never smokers14 and on lung function in asthmatics.15 In the
follow-up study (SAPALDIA 2), we also show a higher probability
of the development of asthma in subjects exposed to ETS.16
In SAPALDIA 2, ambulatory 24-h electrocardiograms (ECG) were
performed in a random sample of participants age >50.
This analysis looks at the effect of ETS exposure on HRV
and explores the role of heart rate and blood pressure in this
context.
Materials and methods
Participants
The SAPALDIA cohort study was designed to measure the
health effects of long-term exposure to air pollutants in the
Swiss adult population. Details of its design and objectives
have been reported elsewhere.17,18 In 1991, a random sample of
the Swiss population was recruited from eight areas
featuring distinct geographical and environmental conditions.
SAPALDIA participants were examined in 1991 and 2001–03 for
risk factors of cardiovascular disease, respiratory symptoms,
pulmonary function evolution and development of lung
diseases.
A random sample of 2000 SAPALDIA 2 participants age >50
who agreed to participate were offered a 24-h ECG recording.
Data on smoking status were collected during an extensive
interview led by trained fieldworkers. Among the 1837 persons
having performed the measurements, 1385 reported that
they had not smoked cigarettes, pipes, cigarillos or cigars in
the last 5 years and were included in this study. Self-reports
were confirmed by end-expiratory carbon monoxide (CO)
measurements using EC50 Micro-Smokerlyzers (BEDFONT,
Rochester, UK); 91 participants were excluded because they
had an end-expiratory CO of >7 ppm, indicating that they
might be smokers.19–22 One participant was excluded because
of a myocardial infarction in the previous 3 months and
four because of digitalis intake in the previous 30 days.
None had a cardiac pacer or anaesthesia (narcosis or spinal
anaesthesia) in the 8 days prior to the ambulatory ECG
recording (Figure 1).
ETS exposure was assessed for different environments
by the question ‘How many hours per day are you exposed to
other people’s tobacco smoke (i) at home (ii) at the workplace
(iii) in bars and restaurants (iv) elsewhere?’ We focused on
exposure to ETS at home and work since these two sources
dominate overall exposure in most subjects and because it is
usually easier to recall routine exposure to ETS at home and at
work than in other places. For seven subjects, information on
ETS exposure was missing. On the basis of previous work,14
ETS exposure was categorized into three exposure groups: none,
62h per day but not none, and42h per day.
Cardiovascular risk factors
Blood pressure was measured twice on the left upper arm with
the subject sitting and at rest, by an automatic device (705CP,
OMRON, Tokyo, Japan) according to WHO recommendations.23
Blood pressure values used in the regression model were the
arithmetic mean of the two measurements. High blood pressure
was defined as either a systolic blood pressure
(SBP) >140mmHg, or a diastolic blood pressure (DBP)
>90mmHg, or having answered yes to the question ‘Do you
have the following condition: Hypertension?’
Body height and weight were measured with participants not
wearing any shoes or coats and body mass index (BMI) was
calculated as weight (kg) divided by height squared (m2). For
two participants, information for calculating BMI was missing.
Data on education, hypertension and current medications
were collected during the interview.
The highest degree of education, which is correlated to
income,24 was used as a proxy for social position.
Blood samples were taken from subjects, and several known
cardiovascular risk factors were determined by the Institute for
Clinical Chemistry of the University Hospital Zu¨rich: A Hitachi
Modular Autoanalyser (Rotkreuz, Switzerland); assays from
Roche Diagnostics (Mannheim, Germany) were used to
measure serum levels of uric acid and total cholesterol (both
enzymatic tests) and high-sensitive C-reactive protein (CRP)
was measured with a latex-enhanced immunoturbidimetric
assay. High-density lipoprotein cholesterol (HDL) was measured
with a homogenous assay (Roche diagnostics, Mannheim,
Germany) using Roche Cobas Integra (Rotkreuz, Switzerland).
HDL values were only used if the participants had a
triglyceride level of 69.4mmol/l. As additional atherogenic
markers, the difference between total cholesterol and HDL
(non-HDL-cholesterol) and the ratio between total cholesterol
and HDL were calculated.
Ethical approval for the study was given by the central ethics
committee of the Swiss Academy of Medical Sciences and the
Cantonal Ethics Committees for each of the eight examination
areas; subjects gave informed consent at the examination.
These procedures were in accordance with the recommenda-
tions of the Helsinki Declaration.
HRV data
For 24-h ECG (Holter) recording, digital devices (Aria, Del Mar
Medical Systems, Irvine, CA) with a frequency response
of 0.0540Hz and a resolution of 128 samples/s were
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used. The recorders were hooked up after the interview.
Three leads (V1, altered V3 with the electrode on the left
midclavicular line on the lowest rib and altered V5 with the
electrode on the left midclavicular line on the lowest rib) were
recorded over 24 h. We excluded the first 2 h of recording to
avoid bias from the effects of methacholine administered in the
preceding broncho-challenge test. Recordings with insufficient
quality (n¼ 32) or <18h (n¼ 30) were not used (Figure 1).
Mean duration of the remaining 1218 recordings was
22.3 2.1 h. Participants were asked to follow their regular
daily life and to fill in a time-activity diary during the
recording time.
All recordings were scanned through a StrataScan 563 (Del
Mar) and interpreted with the interactive method, with a final
visual check of the full disclosure. Mean heart rate per minute
was derived from Holter measurements. The length of each
RR interval was manually validated during this step.
Re-sampling was done at 4Hz. Spectral analysis was performed
by the fast Fourier transform method using sliding 256 PTAs
windows for night periods. For 24-h periods, calculations of RR
intervals were made without sliding window, to allow
measurement of ultralow frequency power (ULF) and of very
low frequency power (VLF). Only normal to normal (NN)
intervals were used, with intervals excluded due to ectopy or
artefacts being replaced by holding the previous coupling
interval level throughout the time interval to the next valid
coupling interval. The standard deviation of all normal to
normal RR intervals (SDNN) and the following frequency
domain variables were calculated: total power (60.40Hz), ULF
(60.0033Hz), VLF (0.0033–0.04Hz), low frequency (LF) power
(0.04–0.15Hz), high frequency (HF) power (0.15–0.40Hz) and
the ratio between LF and HF (LF/HF).
Statistical analysis
Because an initial inspection suggested that the distribution of
the residuals was skewed, the HRV values were log-transformed
before further analysis and the results are presented as percent
differences between exposure groups.
We evaluated the effect of ETS on HRV, heart rate and blood
pressure using a multivariable regression model adjusting for
study site, sex, age and age squared, education, BMI, self-
reported diabetes and beta-blocker intake in the previous
30 days (core model). Sensitivity analysis for additional
potential confounders (hypertension, physical activity, alcohol
drinking, cardioactive medication and cardiovascular risk
factors in the blood) and additional analyses for the period
during sleep at night to exclude shorter-term effects were
carried out. To check whether former smoking would have a
residual effect on cardiac autonomic function, we controlled for
smoking status in a further analysis.
To assess differences of proportions and means in the three
ETS exposure groups in Table 1, Chi-squared-tests and the
Kruskal–Wallis test were performed.
Statistical analysis was performed using the software package
Stata 9.2 (Stata corporation, College Station, TX).
Results
Among the 1218 never smokers and former smokers included
in the final study group, 184 (15%) were regularly exposed to
ETS at home or at work: 104 (8.5%) 62h/day, and 80 (6.6%)
42 h/day.
Table 1 gives an overview of the study population0s
characteristics, categorized by ETS exposure. Subjects without
ETS exposure were slightly older, had a lower BMI and drank
less alcohol.
Table 2 shows geometric means of HRV measures, adjusted
for the covariates of the core model, according to ETS exposure.
In subjects exposed42 h/day to ETS at home or at work, total
power (95% CI 26 to 3%), LF (CI 28 to 1%) and LF/HF
(CI 26 to 3%) were 15% lower than in unexposed subjects.
ULF was 18% (CI 29 to 4%) lower. Although results for HF,
VLF and SDNN showed no substantial difference between
exposed and unexposed subjects, the trend was the same as for
the other outcome variables. Similar results emerged when
we stratified for sex (Supplementary data are available at
International Journal of Epidemiology online). In order to test
possible pathways, we analysed heart rate and blood pressure:
the results are shown in Table 3 as arithmetic means adjusted
for the covariates of the core model. Heart rate was 2.7% (CI 0.1
to 5.5%; P¼ 0.049) higher in subjects exposed42 h/day to ETS
than in unexposed subjects. Systolic blood SBP was similar in
the two groups and DBP was 1.9% (3.0 to 2.9%; P¼ 0.174)
higher in subjects exposed to ETS4 2h/day. Unadjusted results
are presented as online supplementary material.
Figure 2 shows the relationship between ETS exposure and
percent difference in LF, heart rate and DBP with control for
all factors of the core model. There were trends for a lower
LF with increasing ETS exposure and for higher heart rate and
DBP with higher ETS exposure at home or work.
Sensitivity analyses
In order to guard against confounding by factors not considered
in the core model, we conducted sensitivity analyses by
including complementary categories of covariates in the model
each at a time: additional control for physical exercise causing
sweating and physical exercise causing slight shortness of
breath did not change the difference in total power between
the reference group and the highest ETS exposure group
Figure 1 Flow chart of participants and exclusion criteria
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(Supplementary data are available at International Journal of
Epidemiology online). Also, no sizeable change of the results was
seen with additional control for hypertension. The difference
in total power between the reference group and the highest
exposure group slightly increased with additional control for
consumption of red wine and alcoholic beverages or for serum
levels of uric acid, high-sensitive CRP and non-HDL cholesterol
or when subjects taking ACE inhibitors, antiarrhythmic
medication, calcium channel blockers, diuretics or sympatho-
mimetics were excluded. Moreover, results were not sensitive to
excluding education from the model. We could also see no
difference in the influence of educational level on HRV between
men and women (data not shown). Additional analyses of HRV
restricted to the sleep period according to diary information
showed results similar to the analyses of the 24-h measures.
On average, LF power at night was 15.1% (CI: 25 to 4%;
P¼ 0.009) lower in subjects exposed to ETS >2 h/day than in
the reference group. Additional controlling for smoking status
showed little evidence for a residual effect of former smoking.
The strongest effect of former smoking was seen for ULF with
a 5% lower ULF (CI 13 to 2%) in former smokers than in
never smokers.
Discussion
In recent years, there has been increasing evidence that ETS
exposure affects cardiovascular health.5–10,25–27 Our study pro-
vides further evidence that ETS exposure is associated with
cardiac autonomic dysregulation, which may be an intermediate
step in the pathway to cardiac instability.4,28 Our observations
are in agreement with the findings of Pope, who described a
short-term decrease in all HRV domains after acute exposure to
ETS, but with relatively high standard errors in HF.12
LF, which is considered to represent both sympathetic and
parasympathetic activities,29 was lower in subjects with higher
ETS exposure. We also observed ETS-associated increases in
heart rate and, more weakly, in DBP, consistent with increases
in sympathetic stimulation.
Since few people are exposed to ETS during sleep, we
restricted analyses to the sleep period, when acute exposure
can be excluded and found results similar to those of the
24-h measures. Therefore, we think that our findings do not
reflect acute responses.
Table 1 Overview of the study population baseline characteristics by
exposure group
ETS exposure None 62h/day 42h/day
n 1034 (84.9%) 104 (8.5%) 80 (6.6%)
aFemale 556 (53.8%) 53 (51.0%) 41 (51.3%)
aAge (years) 61.0 (SD 6.4) 59.8 (SD 6.2) 58.4 (SD 5.0)
Blood pressure
systolic (mmHg) 132.7 (SD 19.7) 133.7 (SD 21.0) 131.5 (SD 18.6)
diastolic (mmHg) 81.7 (SD 10.8) 82.4 (SD 10.4) 83.5 (SD 11.3)
aBMI (kg/m2) 26.5 (SD 4.3) 27.8 (SD 4.8) 27.4 (SD 4.3)
aSelf-reported
diabetes
44 (4.3%) 4 (3.9%) 3 (3.8%)
aEducation
Primary 93 (9.0%) 15 (14.4%) 4 (5.0%)
Secondary 660 (63.8%) 69 (66.4%) 59 (73.8%)
Tertiary 281 (27.2%) 20 (19.2%) 17 (21.3%)
Light physical activity
62 d/w 496 (48.1%) 55 (52.9%) 42 (52.5%)
42 d/w 536 (51.9%) 49 (47.1%) 38 (47.5%)
Heavy physical activity
61 h/w 763 (74.2%) 77 (74.8%) 54 (67.5%)
41 h/w 266 (25.9%) 26 (25.2%) 26 (32.5%)
Alcohol
<1 glass/day 776 (75.1%) 66 (63.5%) 56 (70%)
>1 glass/day 258 (25.0%) 38 (36.5%) 24 (30.0%)
aBeta-blocker
medication
123 (11.9%) 17 (16.4%) 8 (10.0%)
ACE-inhibitor 64 (6.2%) 6 (5.8%) 6 (7.5%)
Antiarrhythmic
drugs class Iþ III
4 (0.4%) 0 (0.0%) 1 (1.3%)
Calcium
channel blocker
45 (4.4%) 7 (6.7%) 5 (6.3%)
Diuretics 43 (4.2%) 6 (5.8%) 2 (2.5%)
Sympathomimetics 36 (3.5%) 5 (4.8%) 0 (0.0%)
Uric acid [mol/l] 321.1 (SD 81.4) 332.6 (SD 79.0) 331.7 (SD 93.4)
Hs-CRP [mg/l] 2.6 (SD 5.9) 2.4 (SD 4.8) 2.2 (SD 3.2)
Non-HDL-cholesterol
[mmol/l]
4.7 (SD 1.1) 4.8 (SD 1.2) 4.9 (SD 1.2)
a Covariates of the core model.
Table 2 Adjusteda geometric mean HRV according to ETS exposure
HRV variable No current ETS exp. ETS 62h/day ETS42h/day
n 1034 104 80
SDNN [ms] 134.0 (131.8, 136.1) 134.0 (127.4, 140.9) 129.3 (122.1, 136.9)
Total Power [ms2] 3866.7 (3729.6, 4008.8) 3712.1 (3308.78,4164.5) 3270.1 (2868.7, 3727.7)
HF [ms2] 71.3 (67.5, 75.2) 61.5 (51.8, 73.1) 71.2 (58.5, 86.6)
LF [ms2] 233.6 (224.0, 243.7) 210.3(183.8, 240.6) 197.7 (169.6, 230.5)
LF/HF 3.3 (3.2, 3.4) 3.4 (3.0, 3.8) 2.8 (2.4, 3.2)
VLF [ms2] 626.1 (603.4, 649.7) 598.9 (532.5, 673.7) 560.0 (489.8, 640.3)
ULF [ms2] 2741.3 (2634.1, 2852.8) 2671.6 (2352.9, 3033.6) 2256.3 (1952.4, 2607.6)
Values in parentheses are 95% CIs.
a Adjusted for study site, gender, age, education, BMI, diabetes and beta-blocker intake.
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ETS may affect autonomic control of the heart through
activation of neural receptors of the respiratory tract. On the
other hand, gaseous components, soluble fractions of the
particulate component and ultrafine particle components of
ETS may be absorbed in the lung and have additional systemic
effects. In the experimental setting, chronic ETS exposure has
been shown to increase proinflammatory cytokines and arterial
resistance, to decrease concentrations of antioxidants and
to increase lipid peroxidation.30 We found no evidence of
ETS-associated increases in inflammation as measured by CRP
and other causal mechanisms may predominate with low-grade
chronic exposure. Recent work by Bartoli and colleagues31
suggests that particle exposures alter barometric reflexes, a
pathway through which ETS exposure might also influence
HRV.31 Ultrafine particles are associated with oxidative stress,32
as well as with reduced HRV.33
To better understand why exposure to ETS is associated
with lower HRV, it is interesting to compare these effects
with those of active smoking on HRV. In a recent publication,
we showed that active smokers had lower overall and low
to ULF HRV measures than never smokers, which reflect the
dynamic features of sympathetic cardiovascular modulation,
analogous to the results described in this work. The effect of
current smoking compared with never smoking was also
of magnitude similar to the effect shown in this study.17
Thus, we could deduce that active smoking and passive
smoking harm the cardiovascular system through similar toxic
substances.
The consequence of autonomic dysfunction caused by
pollutants such as ETS, air pollution and other factors can be
an increased risk for ventricular arrhythmia in vulnerable
patients or a contribution to the instability of a vascular plaque,
eventually leading to cardiac death.34–36
We measured exposure to ETS using questionnaire data and
used CO measures to validate smoking status. We believe that
self-reporting gives a better estimate for exposure to ETS during
the past year than measurement of biomarkers, which reflect
the level of exposure to passive smoking in the immediate past
with half-lifes of only several hours.37 In the literature,
measurement of exhaled CO in combination with self-reporting
has been described to provide an acceptable degree of discrimi-
nation between smokers and non-smokers.37
Reporting bias might have occurred if participants with lower
HRV had been more likely to report passive exposure to
cigarette smoke. However, this is very unlikely since HRV is not
readily apparent to the participant. Moreover, exposure to ETS
is generally associated with respiratory symptoms and to a
much lesser degree with cardiovascular health. In addition,
we observed a 13% increase of individuals not exposed to
ETS compared with 1991—which would point towards
under—rather than overreporting of ETS.
A recent study has shown that social position expressed as low
employment grade is associated with low HRV.38 In our study,
the effect of ETS exposure on the HRV parameters did not change
Figure 2 Hours of environmental tobacco smoke exposure at home
and at work and low frequency heart rate variability, heart rate and
diastolic blood pressure and respective 95% confidence intervals,
adjusted for study site, sex, age, education, BMI, diabetes and
beta-blocker intake
Table 3 Adjusteda geometric means of heart rate and blood pressure according to ETS exposure
Variable No current ETS exp. ETS 62h/day ETS42h/day
Heart rate [bpm] 73.4 (72.9, 73.9) 73.4 (71.8, 75.1) 75.3 (73.5, 77.2)
SBP [mmHg] 132.7 (131.6, 133.8) 133.5 (130.1, 136.9) 132.6 (128.7, 136.5)
DBP [mmHg] 81.7 (81.1, 82.3) 82.1 (80.2, 84.0) 83.3 (81.1, 85.5)
Values in parentheses are 95% CIs.
SBP: systolic blood pressure, DBP: diastolic blood pressure.
a Adjusted for study site, gender, age, education, BMI, diabetes and beta-blocker intake.
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when we did not account for level of education, indicating that
these results are not likely to be confounded by social position.
In conclusion, our results contribute to the evidence that
exposure to second-hand smoke increases cardiac risk through
cardiac autonomic dysfunction. Health benefits can be expected
if people are protected from passive smoking.
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 ETS has been shown to be a risk factor for cardiovascular disease, but so far little is known about possible mechanisms.
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